Embecta Corp.
As of Oct 22, 2026, Embecta is in Stage 1, the basing phase, now in week 11 (since Aug 12, 2026). It closed at $6.86, 51.6% below its 52-week high and above its 200-day average, which is falling.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is EMBC early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
EMBC among Medical Instruments & Supplies40th of 51 by relative strength
All 51 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | PLSE | Stage 2 · wk 34 | 98 | +1.3% |
| 2 | PDEX | Stage 2 · wk 36 | 97 | −13.3% |
| 3 | HBIO | Stage 2 · wk 11 | 95 | +3.6% |
| 4 | ATRC | Stage 2 · wk 10 | 89 | −1.1% |
| 5 | WST | Stage 2 · wk 24 | 82 | +4.8% |
| 6 | BDX | Stage 2 · wk 11 | 81 | +9.8% |
| 7 | ICUI | Stage 3 · wk 1 | 81 | +3.1% |
| 8 | OSUR | Stage 3 · wk 8 | 75 | −4.8% |
| …40 | EMBC | Stage 1 · wk 11 | 23 | +22.9% |
Embecta: quick answers
What stage is Embecta in?
As of Oct 22, 2026, Embecta (EMBC) is in Stage 1, the basing phase. It entered Stage 1 on Aug 12, 2026 and is in week 11. What the four stages mean
Is Embecta in an uptrend?
Not yet. Embecta is in Stage 1, a base that can come before an uptrend. It trades 4.4% above its 200-day average, which is falling.
How far is Embecta from its 52-week high?
Embecta closed at $6.86 on Oct 22, 2026, 51.6% below its 52-week high of $14.17. Its 52-week low is $2.89.
How has Embecta performed over the past year?
As of Oct 22, 2026, Embecta is down 50.4% over the past year and down 40.0% so far in 2026.
Which sector and industry is Embecta in?
Embecta is in the Medical Instruments & Supplies industry, part of the Health Care sector.
About this companyHealth Care· Medical Instruments & Supplies
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.